New Lifetime High Reached By Natus Medical (BABY)

Trade-Ideas LLC identified Natus Medical (BABY) as a new lifetime high candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

Natus Medical

(

BABY

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Natus Medical as such a stock due to the following factors:

  • BABY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $12.4 million.
  • BABY has traded 29,011 shares today.
  • BABY is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in BABY with the Ticky from Trade-Ideas. See the FREE profile for BABY NOW at Trade-Ideas

More details on BABY:

Natus Medical Incorporated designs, manufactures, and markets newborn care and neurology healthcare products and services worldwide. BABY has a PE ratio of 4. Currently there are 3 analysts that rate Natus Medical a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Natus Medical has been 257,100 shares per day over the past 30 days. Natus Medical has a market cap of $1.6 billion and is part of the health care sector and health services industry. The stock has a beta of 0.57 and a short float of 6% with 6.57 days to cover. Shares are up 33.2% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Natus Medical as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:

  • Powered by its strong earnings growth of 37.50% and other important driving factors, this stock has surged by 40.91% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, BABY should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • NATUS MEDICAL INC has improved earnings per share by 37.5% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, NATUS MEDICAL INC increased its bottom line by earning $1.00 versus $0.74 in the prior year. This year, the market expects an improvement in earnings ($1.52 versus $1.00).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 39.8% when compared to the same quarter one year prior, rising from $7.82 million to $10.94 million.
  • The revenue growth significantly trails the industry average of 37.3%. Since the same quarter one year prior, revenues slightly increased by 5.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • BABY has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. To add to this, BABY has a quick ratio of 2.33, which demonstrates the ability of the company to cover short-term liquidity needs.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...